Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Pharmacyclics LLC.
Pharmacyclics LLC.
Memorial Sloan Kettering Cancer Center
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Regimmune Corporation
Pharmacyclics LLC.
Thomas Jefferson University
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
M.D. Anderson Cancer Center
Kiadis Pharma
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center